Cholestin Arguments Scheduled for May 10

Cholestin Arguments Scheduled for May 10

WASHINGTON--The Food and Drug Administration (FDA) is scheduled to argue the marketing of Cholestin as a dietary supplement on May 10. The arguments are an attempt on the part of the FDA to reverse the decision of a Salt Lake City judge regarding a red yeast rice supplement that contains lovastatin. According to the FDA, that ingredient, present in Cholestin and in prescription cholesterol-reducing medications such as Merck's Mevacor, is a drug.

Share this article: Email, Slashdot, Digg, Del.icio.us, Yahoo!MyWeb, Windows Live Favorites, Furl
Add this article feed to: RSS, My Yahoo, Newsgator, Bloglines